Quick Answer
Aldeyra Therapeutics, Inc. reported Stockholders Equity of $44.25 million for fiscal year 2025.
Aldeyra Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $44.25M | -37.7% |
| 2024 | $71.00M | -40.7% |
| 2023 | $119.80M | -20.7% |
| 2022 | $151.01M | -26.6% |
| 2021 | $205.74M | +245.7% |
| 2020 | $59.51M | +23.8% |
| 2019 | $48.08M | -44.5% |
| 2018 | $86.62M | +118.7% |
| 2017 | $39.60M | +82.9% |
| 2016 | $21.65M | -13.0% |
| 2015 | $24.88M | +295.9% |
| 2014 | $6.28M | +115.6% |
| 2013 | -$40.22M | +26.0% |
| 2012 | -$54.38M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $49.24M | -42.1% | -10.9% |
| June 30, 2025 | $55.29M | -43.8% | -13.1% |
| March 31, 2025 | $63.60M | -43.9% | -10.4% |
| December 31, 2024 | $71.00M | -40.7% | -16.6% |
| September 30, 2024 | $85.10M | -30.8% | -13.4% |
| June 30, 2024 | $98.31M | -24.3% | -13.3% |
| March 31, 2024 | $113.42M | -17.4% | -5.3% |
| December 31, 2023 | $119.80M | -20.7% | -2.6% |
- Aldeyra Therapeutics, Inc. showed a decrease of -37.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, Aldeyra Therapeutics, Inc.’s stockholders equity has grown by 181.4% (from -$54.38 million to $44.25 million).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: